Genetic Subtypes of Systemic Anaplastic Large Cell Lymphoma Show Distinct Differences in PD-L1 Expression and Regulatory and Cytotoxic T Cells in the Tumor Microenvironment.
Adolescent
Adult
Aged
B7-H1 Antigen
/ genetics
Child
Child, Preschool
Female
Gene Expression Regulation, Neoplastic
/ immunology
Humans
Infant
Lymphocytes, Tumor-Infiltrating
/ immunology
Lymphoma, Large-Cell, Anaplastic
/ classification
Male
Middle Aged
T-Lymphocytes, Cytotoxic
/ immunology
T-Lymphocytes, Regulatory
/ immunology
Transcription Factors
/ genetics
Tumor Microenvironment
/ genetics
Tumor Suppressor Proteins
/ genetics
Journal
Applied immunohistochemistry & molecular morphology : AIMM
ISSN: 1533-4058
Titre abrégé: Appl Immunohistochem Mol Morphol
Pays: United States
ID NLM: 100888796
Informations de publication
Date de publication:
01 2020
01 2020
Historique:
entrez:
7
12
2019
pubmed:
7
12
2019
medline:
24
11
2020
Statut:
ppublish
Résumé
Anaplastic large cell lymphomas (ALCL) encompass several subgroups that differ in their clinical presentation, genetic features, and prognosis. We characterized the genetic subgroups of 74 patients with ALCL and correlated programmed death ligand 1 (PD-L1) protein expression and compared the densities and ratios of FOXP3+ T regulatory cells and CD8+ tumor-infiltrating lymphocytes (TILs) in tumor cells and the immune microenvironment. The subgroups included anaplastic lymphoma kinase (ALK)-positive (ALK+) ALCL and ALK-negative (ALK-) ALCL and DUSP22-rearranged and nonrearranged ALK- ALCL. None of our cases represented the TP63-rearrangement ALK- ALCL subgroup. Our results showed that ALK+ ALCL had a higher expression of PD-L1 in the tumor cells, in contrast to ALK- ALCL, which expressed high PD-L1 in tumor-associated macrophages (TAMs). DUSP22-rearranged ALK- ALCL lacked PD-L1 expression in the tumor cells and instead expressed PD-L1 only in TAMs. There was a significant positive correlation of PD-L1 expression between tumor and TAMs in ALK+ ALCL with a negative correlation in ALK- ALCL. Systemic ALCL subgroups had similar densities of CD8+ tumor-infiltrating lymphocytes and FOXP3 T regulatory cells, but differences were observed in the ratio of CD8/FOXP3. Our results suggest that alterations in tumor microenvironment and immune responses exist among systemic ALCL subgroups and these features may account for different clinical behavior and prognosis.
Identifiants
pubmed: 31809310
doi: 10.1097/PAI.0000000000000798
pii: 00129039-202001000-00002
doi:
Substances chimiques
B7-H1 Antigen
0
CD274 protein, human
0
TP63 protein, human
0
Transcription Factors
0
Tumor Suppressor Proteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
10-16Références
Xing X, Feldman AL. Anaplastic large cell lymphoma: ALK positive, ALK negative, and primary cutaneous. Adv Anat Pathol. 2015;22:29–49.
Stein H, Mason D, Gerdes J, et al. The expression of the Hodgkin’s disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood. 1985;66:848–858.
Feldman AL, Harris NL, Stein H, et alSwerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J. Anaplastic large cell lymphoma, ALK-negative. Classification of Tumors of Haematopoietic and Lymphoid Tissues. Lyon, France: International Agency for Reasearch on Cancer; 2017:418–421.
Falini B, Lamant-Rochaix L, Campo E, et alSwerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J. Anaplastic large cell lymphoma, ALK-positive. Classification of Tumors of Haematopoietic and Lymphoid Tissues. Lyon, France: International Agency for Reasearch on Cancer; 2017:413–418.
Willemze R, Paulli M, Kadin MESwerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J. Primary cutaneous CD30-positive T-cell lymphoproliferative disorders. WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues, Revised 4th ed. Lyon: IARC; 2017:P392–P396.
Feldman AL, Harris NL, Stein H, et alSwerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J. Breast implant-associated anaplastic large cell lymphoma. WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues, Revised 4th ed. Lyon: IARC; 2017:P421–P422.
Hapgood G, Savage KJ. The biology and management of systemic anaplastic large cell lymphoma. Blood. 2015;126:17–25.
Stein H, Foss HD, Dürkop H, et al. CD30+ anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood. 2000;96:3681–3695.
Mereu E, Pellegrino E, Scarfò I, et al. The heterogeneous landscape of ALK negative ALCL. Oncotarget. 2017;8:18525–18536.
Feldman AL, Dogan A, Smith DI, et al. Discovery of recurrent t(6;7)(p25.3;q32.3) translocations in ALK-negative anaplastic large cell lymphomas by massively parallel genomic sequencing. Blood. 2011;117:915–919.
Parrilla Castellar ER, Jaffe ES, Said JW, et al. ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. Blood. 2014;124:1473–1480.
Pauken KE, Wherry J. Overcoming T cell exhaustion in infection and cancer. Trends Immunol. 2015;36:265–276.
Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol. 2007;25:267–296.
Hude I, Sasse S, Engert A, et al. The emerging role of immune checkpoint inhibition in malignant lymphoma. Hematologica. 2017;102:2–13.
Peggs KS, Quezada SA, Allison JP. Cell intrinsic mechanisms of T-cell inhibition and application to cancer. Immunol Rev. 2008;224:141–165.
Wilcox RA, Feldman AL, Wada DA, et al. B7-H1 (PD-L1, CD274) suppress host immunity in T-cell lymphoproliferative disorders. Blood. 2009;114:2149–2158.
Xerri L, Chetaille B, Seriari N, et al. Programmed death 1 is a marker of angioimmunoblastic T-cell lymphoma and B-cell small lymphocytic lymphoma/chronic lymphcytic leukemia. Hum Pathol. 2008;39:1050–1058.
Andorsky DJ, Yamada RE, Said J, et al. Programmed death ligand 1 is expressed by non-Hodgkin lymphomas and inhibits the activity of tumor-associated T cells. Clin Cancer Res. 2011;17:4232–4244.
Marzec M, Zhang Q, Goradia M, et al. Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1). Proc Natl Acad Sci USA. 2008;105:20852–20857.
Brown JA, Dorman DM, Ma FR, et al. Blockade of programmed death-1 ligands on dendritic cells enhances T cells activation and cytokine production. J Immunol. 2003;170:1257–1266.
Atsaves V, Tsesmetzis N, Chioureas D, et al. PD-L1 is commonly expressed and transcriptionally regulated by STAT3 and MYC in ALK-negative anaplastic large-cell lymphoma. Leukemia. 2017;31:1633–1637.
Panjwani PK, Charu V, DeLisser M, et al. Programmed death-1 ligands PD-L1 and PD-L2 show distinctive and restricted patterns of expression in lymphoma subtypes. Hum Pathol. 2018;71:91–99.
Marinelli RJ, Montgomery K, Liu CL, et al. The Stanford tissue microarray database. Nucleic Acids Res. 2008;36:D871–D877.
Gentzler R, Hall R, Kunk PR, et al. Beyond melanoma: inhibiting the PD-1/PD-L1 pathway in solid tumors. Immunotherapy. 2016;8:583–600.
Tsuyama N, Sakamot K, Sakata S, et al. Anaplastic large cell lymphoma: pathology, genetics, and clinical aspects. J Clin Exp Hematop. 2017;57:120–142.
Iqbal J, Wilcox R, Naushad H, et al. Genomic signatures in T-cell lymphoma: how can these improve precision in diagnosis and inform prognosis? Blood Rev. 2016;30:89–100.
Gravelle P, Burroni B, Péricart S, et al. Mechanisms of PD-1/PD-L1 expression and prognostic relevance in non-Hodgkin lymphoma: a summary of immunohistochemical studies. Oncotarget. 2017;8:44960–44975.
Luchtel RA, Dasari S, Oishi N, et al. Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with DUSP22 rearragnements. Blood. 2018;132:1386–1398.
Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. Immunol. 2013;13:227–242.
Kono K, Kawaida H, Takahashi A, et al. CD4(+)CD25(+) high regulatory T cells increase with tumor stage in patients with gstric and esophageal cancers. Cancer Immunol Immunother. 2006;55:1064–1071.
Zhu Y, Li M, Mu D, et al. CD8+/FOXP3+ ratio and PD-L1 expression associated with survival in pT3N0M0 stage esophageal squamous cell cancer. Oncotarget. 2016;7:71455–71465.
Que Y, Xiao W, Guan YX, et al. PD-L1 expression is associated with FOXP3+ regulatory T-cell infiltration of soft tissue sarcoma and poor patient prognosis. J Cancer. 2017;8:2018–2025.
Li Z, Dong P, Ren M, et al. PD-L1 expression is associated with tumor FOXP3(+) regulatory T-cell infiltration of breast cancer and poor prognosis of patient. J Cancer. 2016;7:784–793.
Franciso LM, Salinas VH, Brown KE, et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med. 2009;206:3015–3029.
Sledzinska A, Menger L, Bergerhoff K, et al. Negative immune checkpoints on T lymphocytes and their relevance to cancer immunotherapy. Mol Oncol. 2015;9:1936–1965.
Carreras J, Lopes-Guillermo A, Fox BC, et al. FOXP3-positive regulatory T-cells are associated with improved overall survival in follicular lymphoma. Blood. 2006;108:2957–2964.
Tzankov A, Meier C, Hirschmann P, et al. Correlation of high numbers of intratumoral FOXP+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin’s lymphoma. Haematologica. 2008;93:193–200.
Wherry EJ, Kurach M. Molecular and cellular insights into T cell exhaustion. Nature Rev Immunol. 2015;15:486–499.
Gong Y, Chen R, Zhang X, et al. Role of immune microenvironmental factors for improving the IPI-related risk stratification of aggressive B cell lymphoma. Biomed Environ Sci. 2017;30:492–500.
Yang ZZ, Novak AJ, Ziesmer SC, et al. Attenuation of CD8(+) T-cell function by CD4(+)CD25(+) regulatory T cells in B-cell non-Hodgkin’s lymphoma. Cancer Res. 2006;66:10145–10152.
Roychoudhuri R, Eil RL, Restifo NP. The interplay of effector and regulatory T cells in cancer. Curr Opin Immunol. 2015;33:101–111.